Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy

Annals of Medicine

Volumn 42, Issue 5, 2010, Pages 334-343

  Tuomikoski, Pauliina ^a   Haapalahti, Petri ^a   Sarna, Seppo ^b   Ylikorkala, Olavi ^a   Mikkola, Tomi S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiovascular risk; Hot flash; Medroxyprogesterone acetate; Menopause; Transdermal estradiol; Vasomotor symptoms

Indexed keywords

ESTRADIOL; ESTRONE; MEDROXYPROGESTERONE ACETATE; PLACEBO; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; FREE ESTRADIOL INDEX; HEART RATE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77953584334     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853891003796760     Document Type: Article

References (47)

1. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54:11-18
2. Svetkey l P. Management of prehypertension. Hypertension. 2005;45:1056-1061
3. Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BmJ. 2007;335:432-440
4. Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R, et al. Menopause-related blood pressure increase and its relationship to age and body mass index: the simona epidemiological study. J Hypertens. 2005;23:2269-2276
5. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of european cardiologists and gynaecologists. Eur Heart J. 2007;28:2028-2040 (Pubitemid 47579557)
6. Casiglia E, Tikhonoff V, Caff S, Bascelli A, Schiavon L, Guidotti F, et al. Menopause does not affect blood pressure and risk profle, and menopausal women do not become similar to men. J Hypertens. 2008;26:1983-1992
7. Cifkova R, Pitha J, Lejskova M, Lanska V, Zecova S. Blood pressure around the menopause: a population study. J Hypertens. 2008;26:1976-1982
8. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51: 952-959
9. Thurston RC, Sutton-Tyrrell K, Everson-rose SA, Hess R, Matthews KA. Hot fashes and subclinical cardiovascular disease: fndings from the study of Women's Health across the nation Heart study. Circulation. 2008;118:1234-1240
10. Tuomikoski P, Haapalahti P, Ylikorkala O, Mikkola TS. Vasomotor hot fushes and 24-hour ambulatory blood pressure in recently postmenopausal women. Ann med. 2010;42:216-222
11. Stearns V, Ullmer L, Lopéz J, Smith Y, Isaacs C, Hayes D. Hot fushes. Lancet. 2002;360:1851-1861
12. Freedman RR. Pathophysiology and treatment of menopau-sal hot fashes. Semin reprod med. 2005;23:117-125
13. Deecher DC, Dorries K. Understanding the pathophysiol-ogy of vasomotor symptoms (hot fushes and night sweats) that occur in perimenopause, Menopause, and postmeno-pause life stages. Arch Womens ment Health. 2007;10: 247-257
14. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann intern med. 1992;117:1016-1037
15. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, Observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann intern med. 2000;133: 933-941
16. Taskinen MR. Oestrogen replacement therapy and coronary heart disease. Ann med. 1998;30:43-51.
17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmeno-pausal women. Heart and estrogen/progestin replacement study (Hers) research Group. Jama. 1998;280:605-613
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health initiative randomized controlled trial. Jama. 2002;288:321-333
19. Nair GV, Klein KP, Herrington DM. Assessing the role of oestrogen in the prevention of cardiovascular disease. Ann med. 2001;33:305-312
20. Mikkola TS, Clarkson TB. Estrogen replacement therapy, Atherosclerosis, and vascular function. Cardiovasc res. 2002;53:605-619
21. Mikkola TS, Clarkson TB, Notelovitz M. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? ann med. 2004;36:402-413
22. Mikkola TS, Ylikorkala O. Hormone therapy and cardiovascular disease\still much to be learnt. Gynecol endocrinol. 2005;20:116-120
23. Van der schouw YT, Grobbee DE. Menopausal complaints, Oestrogens, and heart disease risk: an explanation for discrepant fndings on the benefts of post-menopausal hormone therapy. Eur Heart J. 2005;26:1358-1361
24. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731
25. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot fash studies. J Clin oncol. 2001;19:4280-4290
26. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective men-opausal symptom relief. Climacteric. 2007;10:120-131
27. Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamäki H, rönnback M, et al. Effect of hot fushes on vascular function; a randomized controlled trial. Obstet Gynecol. 2009;114:777-785
28. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N engl J med. 2006;354:2368-2374
29. Enström I, Lidfeldt J, Lindholm LH, Nerbrand C, Pennert K, Samsioe G. Does blood pressure differ between users and non-users of hormone replacement therapy? The Women's Health in the lund area (WHila) study. Blood Press. 2002;11:240-243
30. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N engl J med. 2003;349:523-534
31. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas. 2004;49:189-203.
32. Samsioe G, Lidfeldt J, Nerbrand C, Nilsson P. The Women's Health in the lund area (WHila) study\an overview. Maturitas. 2010;65:37-45.
33. L'Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HrT? a review. Maturitas. 2008;60:185-201.
34. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005;46:249-254
35. Visvanathan K, Gallicchio L, Schilling C, Babus JK, Lewis LM, Miller SR, et al. Cytochrome gene polymorphisms, Serum estrogens, and hot fushes in midlife women. Obstet Gynecol. 2005;106:1372-1381
36. Woods NF, Mitchell ES, Tao Y, Viernes HM, Stapleton PL, Farin FM. Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the seattle midlife Women's Health study. Menopause. 2006;13:902-910
37. Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J med. 2006;119: s52-60.
38. Schilling C, Gallicchio L, Miller SR, Langenberg P, Zacur H, Flaws JA. Genetic polymorphisms, Hormone levels, and hot fashes in midlife women. Maturitas. 2007;57: 120-131 (Pubitemid 46771023)
39. Malacara JM, Perez-luque EL, Martinez-Garza S, Sanchez-marin FJ. The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women. Maturitas. 2004;49:163-169
40. Takeo C, Negishi E, Nakajima A, Ueno K, Tatsuno I, Saito Y, et al. Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with menopausal symptoms. Gend med. 2005;2:96-105.
41. Kuhl H. Pharmacology of estrogens and progestogens: infuence of different routes of administration. Climacteric. 2005; 8:3-63.
42. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol rev. 2008;60:210-241
43. Hemelaar M, Van der mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil steril. 2008;90:642-672
44. Clarkson TB, Appt SE. MPa and postmenopausal coronary artery atherosclerosis revisited. Steroids. 2003;68:941-951
45. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb vasc Biol. 2004;24:1171-1179
46. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefts\an attempt to interpret the Women's Health initiative results. Gynecol Endocrinol. 2006;22:303-317
47. Shakir YA, Samsioe G, Nyberg P, Lidfeldt J, Nerbrand C. Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of swedish women. The Women's Health in the lund area (WHila) study. Climacteric. 2004;7:274-283 (Pubitemid 39331267)